Vir Biotechnology, Inc. announced that the first participant has been dosed in a Phase 1 trial evaluating the safety, reactogenicity and immunogenicity of VIR-1388, an investigational novel T cell vaccine for the prevention of human immunodeficiency virus (HIV). The Company expects initial data from the Phase 1 trial in the second half of 2024. VIR-1388 is based on the human cytomegalovirus (HCMV) vector platform and is designed to stimulate the body to produce immune cells known as T cells that recognize several HIV proteins in a way that differs from prior investigational HIV vaccines.

VIR-1388 was developed using applied learnings from VIR-1111, the Company's initial investigational proof-of-concept HIV T cell vaccine based on HCMV. The trial is supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and the Bill & Melinda Gates Foundation. NIAID has provided funding throughout the product development lifecycle of VIR-1388, and the Foundation has also supported the Company?s development of therapies for the treatment of HIV, the prevention of tuberculosis and the prevention of malaria.

The Phase 1 trial of VIR-1388 will take place in both domestic and international sites within the federally funded HIV Vaccine Trials Network (HVTN) as study HVTN 142. The HCMV vector is a weakened version of the virus that is designed to deliver the HIV vaccine material to the immune system without causing disease in the trial participants. HCMV has been present in much of the global population for centuries.

Most people living with HCMV experience no symptoms and are unaware that they are living with the virus. HCMV remains detectable in the body for life, which suggests it has the potential to deliver and then safely help the body retain HIV vaccine material for a long period of time, potentially overcoming the waning immunity observed with more short-lived vaccine vectors. Design of the Phase 1 Trial: The randomized, double-blind, placebo-controlled Phase 1 trial (NCT05854381) is evaluating the safety, reactogenicity and immunogenicity of three different doses of VIR-1388 compared with placebo.

The trial is designed to enroll approximately 95 participants ages 18 to 55 who are not living with HIV, with existing antibodies specific to HCMV and in overall good health as determined by medical history, physical exam and laboratory tests. The overall study design includes two parts. Part A is a lead-in phase enrolling a limited number of HCMV-positive persons of non-childbearing potential with a frequent safety monitoring schedule.

Part B will expand enrollment to a broader population of HCMV-positive participants, including persons of childbearing potential. An optional long-term follow-up study will increase study participation for up to three years post first dose. About VIR-1388: VIR-1388 is an investigational subcutaneously administered HIV T cell vaccine based on HCMV that has been designed to elicit abundant T cells that recognize HIV proteins in a way that differs from prior investigational HIV vaccines.

VIR-1388 uses applied learnings from VIR-1111, Vir?s initial investigational proof-of-concept HIV T cell vaccine, with the goal of creating a safe and effective HIV vaccine. About VIR-1111: VIR-1111 is an investigational subcutaneously administered proof-of-concept HIV T cell vaccine based on HCMV that has been designed to elicit abundant T cells that recognize HIV epitopes in a way that differs from prior HIV vaccines.